Use of PCV13 and PPSV23 in adults 65 and older

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Dear Subscribers,

In today’s MMWR, CDC released a new recommendation for the use of pneumococcal vaccines among adults. Adults 65 years or older are now recommended to get the pneumococcal conjugate vaccine (PCV13, Prevnar-13®) and the pneumococcal polysaccharide vaccine (PPSV23, Pneumovax®23).

As part of the new recommendation, adults 65 years of age or older who have not previously received any pneumococcal vaccines or whose previous vaccination history is unknown should receive a dose of PCV13 first, followed 6-12 months later by a dose of PPSV23. Adults 65 years of age or older who have previously received PPSV23 should receive PCV13 at least 1 year since their most recent dose of PPSV23.

In addition to the new recommendation for pneumococcal vaccination of adults 65 years or older, it’s important to remember that pneumococcal vaccines are also recommended for adults 19 years or older with certain health conditions and lifestyles.

To access the MMWR, go to For more information on pneumococcal vaccination, visit

Modify/Update Subscriber Preferences | Unsubscribe | Send Feedback | Learn about CDC Updates

Questions or problems? Please contact support.

CDC 24/7 – Saving Lives, Protecting People, Saving Money.… Dept of Health and Human Services Logo Learn Vital Information about Reducing Sodium in Children's Diets.
CDC on Facebook CDC on Twitter CDC YouTube Channel

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: